Literature DB >> 19629003

Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor.

Barbara Mroczko1, Marta Lukaszewicz-Zajac, Urszula Wereszczynska-Siemiatkowska, Magdalena Groblewska, Mariusz Gryko, Boguslaw Kedra, Grazyna Jurkowska, Maciej Szmitkowski.   

Abstract

OBJECTIVE: Pancreatic cancer (PC) is a malignant tumor with high mortality. Aggressive growth and metastases of PC are the result of basement membrane degradation that may be attributed to the action of matrix metalloproteinase-9 (MMP-9). The aim of the study was to determine the diagnostic and prognostic significance of the measurements of serum MMP-9 and tissue inhibitor of metalloproteinase-1 (TIMP-1) in patients with PC.
METHODS: The study involved 78 patients with PC, 45 with chronic pancreatitis, and 70 healthy subjects. We assayed the serum concentrations of MMP-9, TIMP-1, and classic tumor markers (carbohydrate antigen 19-9 and carcinoembryonic antigen) and defined the prognostic value and the diagnostic criteria for all the proteins tested.
RESULTS: In the patients with PC, the serum levels of MMP-9, TIMP-1, and the tumor markers were higher as compared with those in the patients with chronic pancreatitis and the healthy subjects. The diagnostic sensitivity and the area under the receiver operating characteristic curve for TIMP-1 were higher than for MMP-9 and the tumor markers. The elevated preoperative concentration of MMP-9 was a significant independent prognostic factor for the patients' survival.
CONCLUSIONS: These findings indicate a potential clinical significance of serum TIMP-1 and MMP-9 measurements in the diagnosis and prognosis of patients with PC, respectively.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19629003     DOI: 10.1097/MPA.0b013e3181a488a0

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  26 in total

Review 1.  Pancreatic cancer screening.

Authors:  Eun Ji Shin; Marcia Irene Canto
Journal:  Gastroenterol Clin North Am       Date:  2012-01-05       Impact factor: 3.806

Review 2.  Strategies for discovering novel pancreatic cancer biomarkers.

Authors:  Alison Chan; Eleftherios P Diamandis; Ivan M Blasutig
Journal:  J Proteomics       Date:  2012-09-28       Impact factor: 4.044

3.  Matrix metalloproteinase-9 is consistently expressed in Hodgkin/Reed-Sternberg cells and has no impact on survival in patients with Epstein-Barr virus (EBV)-related and non-related Hodgkin lymphoma in Brazil.

Authors:  Eni M Souza; Otávio C G Baiocchi; Maria A Zanichelli; Antonio C Alves; Marianne G Assis; Joyce M K Silva; Cristine Dobo; José S R Oliveira
Journal:  Med Oncol       Date:  2011-09-16       Impact factor: 3.064

Review 4.  Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview.

Authors:  S Bünger; T Laubert; U J Roblick; J K Habermann
Journal:  J Cancer Res Clin Oncol       Date:  2010-12-31       Impact factor: 4.553

5.  Serum biomarker panels for the detection of pancreatic cancer.

Authors:  Randall E Brand; Brian M Nolen; Herbert J Zeh; Peter J Allen; Mohamad A Eloubeidi; Michael Goldberg; Eric Elton; Juan P Arnoletti; John D Christein; Selwyn M Vickers; Christopher J Langmead; Douglas P Landsittel; David C Whitcomb; William E Grizzle; Anna E Lokshin
Journal:  Clin Cancer Res       Date:  2011-02-15       Impact factor: 12.531

Review 6.  Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in the tumors of central nervous system (CNS).

Authors:  Marta Lukaszewicz-Zając; Barbara Mroczko; Johannes Kornhuber; Piotr Lewczuk
Journal:  J Neural Transm (Vienna)       Date:  2013-12-24       Impact factor: 3.575

Review 7.  The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates.

Authors:  Katherine E Poruk; D Z Gay; K Brown; J D Mulvihill; K M Boucher; C L Scaife; M A Firpo; S J Mulvihill
Journal:  Curr Mol Med       Date:  2013-03       Impact factor: 2.222

Review 8.  Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets.

Authors:  Elin Hadler-Olsen; Jan-Olof Winberg; Lars Uhlin-Hansen
Journal:  Tumour Biol       Date:  2013-05-17

9.  Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.

Authors:  Katherine E Poruk; Matthew A Firpo; Courtney L Scaife; Douglas G Adler; Lyska L Emerson; Kenneth M Boucher; Sean J Mulvihill
Journal:  Pancreas       Date:  2013-03       Impact factor: 3.327

10.  ERK2-regulated TIMP1 induces hyperproliferation of K-Ras(G12D)-transformed pancreatic ductal cells.

Authors:  Gregory P Botta; Maximilian Reichert; Mauricio J Reginato; Steffen Heeg; Anil K Rustgi; Peter I Lelkes
Journal:  Neoplasia       Date:  2013-04       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.